Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases

Stereotactic ablative body radiotherapy for lung cancer.

Lung stereotactic ablative radiotherapy (SABR) is a method of delivering high 'ablative' doses of radiotherapy to tumours in the lung. It was developed at the Karolinska Institute in the early 1990s using the methods established in cranial radiosurgery with multiple beams prescribed to an isodose and using a custom designed stereotactic body frame for immobilisation. Since then, aligned with th...

Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligometastases

Objectives: To evaluate the feasibility, efficacy and toxicity of robotic stereotactic body radiotherapy for the treatment of unresectable hepatic oligometastases. Methods: Between 09/2010 and 06/2015, 43 consecutive patients (19 female, 24 male, median age at treatment: 69.8 ; range, 43-83 years) with up to three synchronous or metachronous hepatic oligometastases were referred for Cyberknife ...

Stereotactic ablative body radiotherapy for hepatocellular carcinoma or cholangiocarcinoma

New Strategies in Stereotactic Radiotherapy for Oligometastases.

Patients with metastatic solid tumors are usually treated with palliative intent. Systemic therapy and palliative radiation are often used, with the goals of prolonging survival or maintaining quality of life, but not of cure. In contrast to this paradigm, the theory of oligometastasis suggests that some patients who have a small number of metastases may be amenable to cure if all lesions can b...

Stereotactic ablative radiotherapy for lung cancer

Stereotactic ablative radiotherapy (SABR), which is also referred to as stereotactic body radiotherapy (SBRT), is defined as “the precise irradiation of an image defined extra-cranial lesion associated with the use of high radiation dose in a small number of fractions”. SABR is a relatively recent advance in the treatment of small peripheral non-small cell lung tumours. The concept of SABR was ...